NF-κB Pathway Inhibitor

New compounds to treat cancer

  • Inhibits the NF-κB pathway
  • Causes degradation of IKKβ and IKKα
  • Nanomolar potency in cell-based studies

 
Licensing manager: Matt Boehm, Ph.D. mboehm@unmc.edu or 402-559-2166
 

SKU: 428 Category: Tags: , ,

Description

UNMC scientists invent new compounds to treat cancer

Amarnath Natarajan

Amarnath Natarajan, Ph.D.

Researchers at the University of Nebraska Medical Center created a molecule capable of specifically inhibiting the NF-κB pathway, a key target involved in a variety of cancers and other diseases.
 
The NF-κB pathway is often overactive in a number of cancers. Therefore, new ways to shut off this pathway could yield important new cancer treatments.
 
Amarnath Natarajan, Ph.D., and his team developed a small molecule called 36-252 that destroys key members of the NF-κB pathway—specifically the proteins IKKβ and IKKα. In ovarian cancer cell studies, 36-252 effectively inhibited cell growth at nanomolar concentrations, stimulated cell death (apoptosis), and effectively inhibited NF-κB activity. 36-252 was also effective at destroying ovarian cancer stem-like cells.
 
UNeMed is interested in forming collaborations with industry to further explore the potential of 36-252 as a novel therapy of the treatment of cancer and other diseases associated with overactive NF-κB.
 
To discuss licensing opportunities please contact Matt Boehm, Ph.D., at mboehm@unmc.edu or 402-559-2166.
 

Additional Information

Provisional patent application filed.